Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
arcticnovartis
Wed, 02/04/2026 – 07:04
Read more about Novartis erzielte im Jahr 202…
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
arcticnovartis
Wed, 02/04/2026 – 07:04
Read more about Novartis delivered high single-digit sales growth, achieved 40% core margi…
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis
Fri, 01/16/2026 – 18:02
Read more about Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
De…
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis
Fri, 01/16/2026 – 18:02
Read more about Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
De…
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
arcticnovartis
Fri, 01/09/2026 – 16:32
Read more about Novartis to add radioligand therapy manufa…
Novartis and US government reach agreement on lowering drug prices in the US
arcticnovartis
Fri, 12/19/2025 – 20:34
Read more about Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to tak…
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis
Tue, 12/09/2025 – 13:34
Read more about Novartis ianalumab significantly extends disease control in …
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
arcticnovartis
Tue, 11/25/2025 – 07:19
Read more about Novartis data underscore pioneering scientific innovation in hematology and oncology at AS…
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
arcticnovartis
Mon, 11/24/2025 – 23:19
Read more about Novartis receives FDA appr…